Cargando…

Randomized Double-blind Placebo-controlled Proof-of-concept Trial of Resveratrol for Outpatient Treatment of Mild Coronavirus Disease (COVID-19)

Mostrar otras versiones (1)

Resveratrol is a polyphenol that has been well studied and has demonstrated anti-viral and anti-inflammatory properties that might mitigate the effects of COVID-19. Outpatients (N=105) were recruited from central Ohio in late 2020. Participants were randomly assigned to receive placebo or resveratro...

Descripción completa

Detalles Bibliográficos
Autores principales:	McCreary, Marvin R., Schnell, Patrick M., Rhoda, Dale A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Journal Experts 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452104/ https://www.ncbi.nlm.nih.gov/pubmed/34545357 http://dx.doi.org/10.21203/rs.3.rs-861831/v1

Ejemplares similares

Randomized double-blind placebo-controlled proof-of-concept trial of resveratrol for outpatient treatment of mild coronavirus disease (COVID-19)
por: McCreary, Marvin R., et al.
Publicado: (2022)

Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer’s disease
por: Cummings, Jeffrey L., et al.
Publicado: (2016)

Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial
por: Bloch, Yehudit, et al.
Publicado: (2021)

Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial
por: Dubée, Vincent, et al.
Publicado: (2021)

A randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine monohydrate as adjunctive treatment for bipolar depression
por: Toniolo, Ricardo Alexandre, et al.
Publicado: (2017)

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
por: Turner, R. Scott, et al.
Publicado: (2015)

Levetiracetam for the treatment of mild cognitive impairment in Parkinson’s disease: a double-blind controlled proof-of-concept trial protocol
por: Dissanayaka, Nadeeka, et al.
Publicado: (2023)

Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept
por: Kaddurah-Daouk, R, et al.
Publicado: (2011)

Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults
por: Koblan, Kenneth S, et al.
Publicado: (2015)

Relieving acute pain (RAP) study: a proof-of-concept protocol for a randomised, double-blind, placebo-controlled trial
por: Colloca, Luana, et al.
Publicado: (2019)

Efficacy and Safety of ASP0819 in Patients with Fibromyalgia: Results of a Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial
por: Arnold, Leslie M, et al.
Publicado: (2020)

An Investigation of Levetiracetam in Alzheimer’s Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept study
por: Sen, Arjune, et al.
Publicado: (2021)

Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019
por: Streinu-Cercel, Anca, et al.
Publicado: (2022)

Proof-of-Concept Double-Blind Placebo-Controlled Trial Measuring Cartilage Composition in Early Rheumatoid Arthritis under TNF-α-Inhibitor Therapy
por: Frenken, Miriam, et al.
Publicado: (2023)

A Randomised, Double-Blind, Placebo-Controlled Crossover Trial of Resveratrol Supplementation for Prophylaxis of Hormonal Migraine
por: Dzator, Jemima S. A., et al.
Publicado: (2022)

Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2×2 clinical trial
por: Savitz, Jonathan, et al.
Publicado: (2012)

The use of equine chondrogenic‐induced mesenchymal stem cells as a treatment for osteoarthritis: A randomised, double‐blinded, placebo‐controlled proof‐of‐concept study
por: Broeckx, S. Y., et al.
Publicado: (2019)

Favipiravir for Treatment of Outpatients With Asymptomatic or Uncomplicated Coronavirus Disease 2019: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial
por: Holubar, Marisa, et al.
Publicado: (2022)

Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options
por: McCreary, Erin K, et al.
Publicado: (2020)

Neuroprotective Effect of Trans-Resveratrol in Mild to Moderate Alzheimer Disease: A Randomized, Double-Blind Trial
por: Gu, Jiachen, et al.
Publicado: (2021)

The erythropoietin neuroprotective effect: assessment in coronary artery bypass graft surgery (TENPEAKS) – a randomized, double-blind, placebo-controlled, proof-of-concept clinical trial
por: Haljan, G, et al.
Publicado: (2006)

Ciclosporin to Protect Renal function In Cardiac Surgery (CiPRICS): a study protocol for a double-blind, randomised, placebo-controlled, proof-of-concept study
por: Ederoth, Per, et al.
Publicado: (2016)

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
por: Baeten, Dominique, et al.
Publicado: (2018)

11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial
por: Othonos, Nantia, et al.
Publicado: (2023)

The efficacy of resveratrol in controlling hypertension: study protocol for a randomized, crossover, double-blinded, placebo-controlled trial
por: Movahed, Ali, et al.
Publicado: (2016)

Development of a Lozenge for Oral Transmucosal Delivery of Trans-Resveratrol in Humans: Proof of Concept
por: Blanchard, Otis L., et al.
Publicado: (2014)

A phase IIa proof-of-concept, placebo-controlled, randomized, double-blind, crossover, single-dose clinical trial of a new class of bronchodilator for acute asthma
por: Swystun, Veronica, et al.
Publicado: (2018)

Cannabidiol (CBD) and Δ(9)-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial
por: Suraev, Anastasia, et al.
Publicado: (2020)

A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis
por: Allanore, Yannick, et al.
Publicado: (2020)

First use of cenerimod, a selective S1P(1) receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study
por: Hermann, Viktoria, et al.
Publicado: (2019)

The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study
por: Schmidt, Mark E., et al.
Publicado: (2020)

Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial
por: Samaei, Areoo, et al.
Publicado: (2020)

Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19
por: Bosaeed, Mohammad, et al.
Publicado: (2021)

Correction: First use of cenerimod, a selective S1P(1) receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study
Publicado: (2020)

Mild Mitochondrial Uncoupling Decreases Experimental Atherosclerosis, A Proof of Concept
por: Dorighello, Gabriel G, et al.
Publicado: (2022)

Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance
por: Rodrigues, Cristhieni, et al.
Publicado: (2021)

Randomized, Double-Blind, Placebo-Controlled Trial of a Throat Spray with Selected Lactobacilli in COVID-19 Outpatients
por: De Boeck, Ilke, et al.
Publicado: (2022)

Bosentan for high-risk outpatients with COVID-19 infection: a randomized, double blind, placebo-controlled trial
por: Shahbazi, Shaahin, et al.
Publicado: (2023)

Methylphenidate for Mild Cognitive Impairment: An Exploratory 3-Day, Randomized, Double-Blind, Placebo-Controlled Trial
por: Press, Yan, et al.
Publicado: (2021)

Double-blind randomized proof-of-concept trial of canakinumab in patients with COVID-19 associated cardiac injury and heightened inflammation
por: Cremer, Paul C, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sk4g7nffsted6o972mhefjrcob